- Home
- CMMB vs EQS Comparison
CMMB vs EQS Comparison
Compare CMMB & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- EQS
- Stock Information
- Founded
- CMMB 2004
- EQS 1991
- Country
- CMMB Israel
- EQS United States
- Employees
- CMMB N/A
- EQS N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- EQS Finance Companies
- Sector
- CMMB Health Care
- EQS Finance
- Exchange
- CMMB Nasdaq
- EQS Nasdaq
- Market Cap
- CMMB 22.0M
- EQS 20.1M
- IPO Year
- CMMB N/A
- EQS N/A
- Fundamental
- Price
- CMMB $0.95
- EQS $1.72
- Analyst Decision
- CMMB Strong Buy
- EQS
- Analyst Count
- CMMB 2
- EQS 0
- Target Price
- CMMB $8.50
- EQS N/A
- AVG Volume (30 Days)
- CMMB 125.0K
- EQS 44.9K
- Earning Date
- CMMB 08-20-2025
- EQS 01-01-0001
- Dividend Yield
- CMMB N/A
- EQS N/A
- EPS Growth
- CMMB N/A
- EQS N/A
- EPS
- CMMB N/A
- EQS N/A
- Revenue
- CMMB N/A
- EQS $1,329,000.00
- Revenue This Year
- CMMB N/A
- EQS N/A
- Revenue Next Year
- CMMB N/A
- EQS N/A
- P/E Ratio
- CMMB N/A
- EQS N/A
- Revenue Growth
- CMMB N/A
- EQS 152.66
- 52 Week Low
- CMMB $0.87
- EQS $0.74
- 52 Week High
- CMMB $2.55
- EQS $2.11
- Technical
- Relative Strength Index (RSI)
- CMMB 17.79
- EQS 85.24
- Support Level
- CMMB $0.87
- EQS $1.35
- Resistance Level
- CMMB $1.01
- EQS $2.11
- Average True Range (ATR)
- CMMB 0.06
- EQS 0.11
- MACD
- CMMB -0.01
- EQS 0.02
- Stochastic Oscillator
- CMMB 23.78
- EQS 48.68
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.